Emerging Roles of Cancer Stem Cells in Bladder Cancer Progression, Tumorigenesis, and Resistance to Chemotherapy: A Potential Therapeutic Target for…

Bladder cancer (BC) is a complex and highly heterogeneous stem cell disease associated with high morbidity and mortality rates if it is not treated properly. Early diagnosis with personalized therapy and regular follow-up are the keys to a successful outcome. Cancer stem cells (CSCs) are the leading power behind tumor growth, with the ability of self-renewal, metastasis, and resistance to conventional chemotherapy. The fast-developing CSC field with robust genome-wide screening methods has found a platform for establishing more reliable therapies to target tumor-initiating cell populations. However, the high heterogeneity of the CSCs in BC disease remains a large issue. Therefore, in the present review, we discuss the various types of bladder CSC heterogeneity, important regulatory pathways, roles in tumor progression and tumorigenesis, and the experimental culture models. Finally, we describe the current stem cell-based therapies for BC disease.

Cells. 2020 Jan 17*** epublish ***

Amira Abugomaa, Mohamed Elbadawy, Hideyuki Yamawaki, Tatsuya Usui, Kazuaki Sasaki

Laboratory of Veterinary Pharmacology, Department of Veterinary Medicine, Faculty of Agriculture, Tokyo University of Agriculture and Technology, 3-5-8 Saiwai-cho, Fuchu, Tokyo 183-8509, Japan., Laboratory of Veterinary Pharmacology, School of Veterinary Medicine, Kitasato University, Towada, Aomori 034-8628, Japan.

PubMed http://www.ncbi.nlm.nih.gov/pubmed/31963556

The rest is here:
Emerging Roles of Cancer Stem Cells in Bladder Cancer Progression, Tumorigenesis, and Resistance to Chemotherapy: A Potential Therapeutic Target for...

Early onset Parkinsons might begin in the womb: Prevention a possibility – The New Daily

An intriguing experiment has led researchers to conclude that people who develop early-onset Parkinsons disease between the age of 21 and 50 may have been born with abnormal brain cells that go undetected for decades.

These disordered cells allow gradual accumulation of the -synuclein protein that forms abnormal deposits in the brain, and dysregulated lysosomal proteins that ordinarily play a role in clearing abnormal proteins from cells.

The researchers from Cedars-Sinai Medical Center say they are investigating an FDA approved skin cancer drug they believe might help correct these abnormalities before they become symptomatic.

In other words, they suggest that early-onset Parkinsons the form of the disease that Michael J. Fox was diagnosed with at the age of 29 may be treatable or even prevented. Its an astonishing claim.

To perform the study, the research team generate pluripotent stem cells master cells that can potentially produce any cell or tissue the body needs to repair itself from blood cells of three patients with young-onset Parkinsons disease.

The patients were aged 30-39 and had no known familial history of the disease and no Parkinsons disease mutations.

When generated in the laboratory, these master cells called induced pluripotent stem cells (iPSCs). In their experiment, the Cedars-Sinai researchers described this process as taking adult blood cells back in time to a primitive embryonic state.

The team used the stem cells to produce dopamine neurons from each patient and then cultured them in a dish and analysed the neurons functions.

In Parkinsons patients, brain neurons that make dopamine a neurotransmitter that works to coordinate muscle movement become impaired or die.

Our technique gave us a window back in time to see how well the dopamine neurons might have functioned from the very start of a patients life, said Dr Clive Svendsen, PhD, director of the Cedars-Sinai Board of Governors Regenerative Medicine Institute, and the studys senior author.

According to a statement from Cedars-Sinai, the researchers detected two key abnormalities in the dopamine neurons in the dish:

Dr Svendsen said the experiment allowed the researchers to see the very first signs of young-onset Parkinsons.

It appears that dopamine neurons in these individuals may continue to mishandle alpha-synuclein over a period of 20 or 30 years, causing Parkinsons symptoms to emerge.

The investigators went further, using their iPSC to test a number of drugs that might reverse the lab-born abnormalities.

They found that that one drug, PEP005 already approved by the Food and Drug Administration for treating pre-cancers of the skin reduced the elevated levels of alpha-synuclein in both the dopamine neurons in the dish and in laboratory mice.

The drug also countered another abnormality they found in the patients dopamine neurons elevated levels of an active version of an enzyme called protein kinase C. However, the role of this enzyme version in Parkinsons is not clear.

The drug PEP005 is only available in gel form and the researchers plans to investigate how it might be delivered to the brain to potentially treat or prevent young-onset Parkinsons.

In Parkinsons disease, the symptoms including slowness of movement, rigid muscles, tremors, loss of balance and impaired mood control get worse over time. In most cases, the exact cause of neuron failure is unclear, and there is no known cure.

Just about every week, a new insight into the disease is published. Last week, The New Daily reported on new research that found living less than 50 metres from a major road or less than 150 metres from a highway has been linked to significantly higher incidence of dementia and Parkinsons disease.

In 2018, we published an exciting Australian study that suggested subject to clinical testing the inflammation of the brain that causes so much of the progressive damage in Parkinsons disease (PD) could be halted by taking a single pill each day.

Both these studies might eventually prove to be correct. But its a long wait for the more than 10 million sufferers worldwide and their families.

This latest study could be a game-changer. But it could just as easily wither on the vine. Still, better to take heart than not.

Most patients are 60 or older when they are diagnosed, about 10 per cent are between 21 and 50 years old. .

Young-onset Parkinsons is especially heartbreaking because it strikes people at the prime of life, said Dr Michele Tagliati, director of the Movement Disorders Program, vice chair and professor in the Department of Neurology at Cedars-Sinai, and co-author of the study.

This exciting new research provides hope that one day we may be able to detect and take early action to prevent this disease in at-risk individuals.

Read more:
Early onset Parkinsons might begin in the womb: Prevention a possibility - The New Daily

Global Stem Cell Banking Market Analysis, Trends, and Forecasts 2019-2025 – ResearchAndMarkets.com – Business Wire

DUBLIN--(BUSINESS WIRE)--The "Stem Cell Banking - Market Analysis, Trends, and Forecasts" report has been added to ResearchAndMarkets.com's offering.

The global market for Stem Cell Banking is projected to reach US$9.9 billion by 2025, driven by their growing importance in medicine given their potential to regenerate and repair damaged tissue.

Stem cells are defined as cells with the potential to differentiate and develop into different types of cells. Different accessible sources of stem cells include embryonic stem cells, fetal stem cells, peripheral blood stem cells, umbilical cord stem cells, mesenchymal stem cells (bmMSCs) and induced pluripotent stem cells. Benefits of stem cells include ability to reverse diseases like Parkinsons by growing new, healthy and functioning brain cells; heal and regenerate tissues and muscles damaged by heart attack; address genetic defects by introducing normal cells; reduce mortality among patients awaiting donor organs for transplant by regenerating healthy cells and tissues as an alternative to donated organs. While currently valuable in bone marrow transplantation, stem cell therapy holds huge potential in treating a host of common chronic diseases such as diabetes, heart disease (myocardial infarction), Parkinsons disease, spinal cord injury, arthritis, and amyotrophic lateral sclerosis. The technology has the potential to revolutionize public health.

The growing interest in regenerative medicine which involves replacing, engineering or regenerating human cells, tissues or organs, will push up the role of stem cells. Developments in stem cells bioprocessing are important and will be key factor that will influence and help regenerative medicine research move into real-world clinical use. The impact of regenerative medicine on healthcare will be comparable to the impact of antibiotics, vaccines, and monoclonal antibodies in current clinical care. With global regenerative medicine market poised to reach over US$45 billion 2025, demand for stem cells will witness robust growth.

Another emerging application area for stem cells is in drug testing in the pharmaceutical field. New drugs in development can be safely, accurately, and effectively be tested on stem cells before commencing tests on animal and human models. Among the various types of stem cells, umbilical cord stem cells are growing in popularity as they are easy and safe to extract. After birth blood from the umbilical cord is extracted without posing risk either to the mother or the child. As compared to embryonic and fetal stem cells which are saddled with safety and ethical issues, umbilical cord is recovered postnatally and is today an inexpensive and valuable source of multipotent stem cells. Until now discarded as waste material, umbilical cord blood is today acknowledged as a valuable source of blood stem cells. The huge gap between newborns and available cord blood banks reveals huge untapped opportunity for developing and establishing a more effective banking system for making this type of stem cells viable for commercial scale production and supply. Umbilical cord and placenta contain haematopoietic blood stem cells (HSCs). These are the only cells capable of producing immune system cells (red cells, white cells and platelet).

HSCs are valuable in the treatment of blood diseases and successful bone marrow transplants. Also, unlike bone marrow stem cells, umbilical cord blood has the advantage of having 'off-the-shelf' uses as it requires no human leukocyte antigen (HLA) tissue matching. Developments in stem cell preservation will remain crucial for successful stem cell banking. Among the preservation technologies, cryopreservation remains popular. Development of additives for protecting cells from the stresses of freezing and thawing will also be important for the future of the market. The United States and Europe represent large markets worldwide with a combined share of 60.5% of the market. China ranks as the fastest growing market with a CAGR of 10.8% over the analysis period supported by the large and growing network of umbilical cord blood banks in the country. The Chinese government has, over the years, systematically nurtured the growth of umbilical cord blood (UCB) banks under the 'Developmental and Reproductive Research Initiation' program launched in 2008. Several hybrid public-private partnerships and favorable governmental licensing policies today are responsible for the current growth in this market.

Companies Mentioned

Key Topics Covered:

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE

III. MARKET ANALYSIS

GEOGRAPHIC MARKET ANALYSIS

UNITED STATES

CANADA

JAPAN

CHINA

EUROPE

FRANCE

GERMANY

ITALY

UNITED KINGDOM

REST OF EUROPE

ASIA-PACIFIC

REST OF WORLD

IV. COMPETITION

V. CURATED RESEARCH

For more information about this report visit https://www.researchandmarkets.com/r/9b2ra3

Read the original:
Global Stem Cell Banking Market Analysis, Trends, and Forecasts 2019-2025 - ResearchAndMarkets.com - Business Wire

The Future of Antivenom May Involve Mini Lab-Grown Snake Glands – Smithsonian.com

For the first time, scientists have grown miniature, venom-producing glands in the lab using coral snake embryos, according to a news study published in the journal Cell. Why might researchers want to create artificial venom glands, you ask?

The project was initially aimed to establish proof-of-concept more than anything else. Three graduate students at the Hubrecht Institute in the Netherlands had wondered: If lab-grown organs could be made that acted like mouse and human tissues, would it work for other animals, like reptiles?

Luckily, they were working in molecular geneticist Hans Clevers lab. Clevers is a prominent expert in stem cell research who pioneered research on the lab-grown organ imitationscalled organoidsa decade ago. Since then, researchers have created miniature human kidneys, livers, and brains in petri dishes.

On Fridays, members of the Clevers Lab are allowed to work on unstructured projects. To put their question to the test, Clevers students Yorick Post, Jens Puschhof, and Joep Beumer, would need a source of reptilian stem cells. As it happened, one of the researchers knew a guy: a snake breeder who could supply them with fertilized eggs, as STAT News Andrew Joseph reports.

They started with the egg of a Cape coral snake, removing the embryos venom glands and placing them in a dish. Then, they followed nearly the same protocol as they did with human cells, giving the cells ample supply of growth-inducing chemicals and storing them at a comfortable temperatureabout 89 degrees Fahrenheit, about ten degrees lower than the temperature used for human cells.

Soon, the plates held one-millimeter-long white blobs producing dangerous venom. With the organoids alive and well, the researchers told Clevers what theyd done, Leslie Nemo at Discover reports. If theyd told him beforehand, he would have told them it probably wouldnt work, Clevers tells the Atlantics Ed Yong. The chemicals they used were designed for human stem cells, and very little was known about stem cells in snakes. Still, the researchers were able to grow organoids from nine species of snakes.

Its a breakthrough, University of Costa Rica snake venom toxicologist Jos Mara Gutirrez, who was not involved in the study, tells Erin Malsbury at Science magazine. This work opens the possibilities for studying the cellular biology of venom-secreting cells at a very fine level, which has not been possible in the past, Malsbury says.

By looking closely at the organoids, Clevers team gained new insight into how multiple kinds of cells work together to produce the specific mixture of toxins and proteins that results in fully-developed venom.

Venomous snake bites kill between 81,000 and 138,000 people every year, according to the World Health Organization, and cause three times as many amputations and disabilities. The antidote to a snakebite is an antivenom, but each of thousands of venomous snakes have a different biteeach requiring a unique treatment. Even snakes of the same species can produce a slightly different venoms if they live in different regions.

Right now, antivenoms are produced using much the same process as was invented in the 19th century: a live snake is milked for its venom, that venom is injected into a horse. Horses have been used for antivenom production for years because of their docile nature and big veins, as Douglas Main wrote for Popular Mechanics in 2016. They are first injected with adjuvant, which stimulates their immune system to produce enough antibodies to neutralize the venom. Then, researchers take a sample of their blood and separate the antivenom from other component of blood, like plasma, in a centrifuge.

Clevers now hopes to create a bank of dozensand eventually thousandsof organoids from dangerous snakes and other reptiles that could aid in the effort to manufacture effective antivenoms.

"We could just sample one tissue once, and we have a source of [that snakes] venom for eternity," Clevers tells Discover.

Clevers is working with the Dutch biologist Freek Vonk, who he calls the Dutch Steve Irwin, to get samples of the snake species he hopes to include in the venom gland biobank. (Vonk works at Naturalis Biodiversity Center in Leiden and also has some excellent Dutch science tunes available on Spotify.)

With venom from organoids more easily available, the hope is to skip the horse in the antitoxin-production process. Researchers could instead use the organoid-produced venom to test an array of molecules for neutralizing abilities.

It will be interesting to see how the cost of producing venom using this system compares to the cost of purchasing venom milked from live snakes, since cost of antivenom is a key impediment to its wider use in countries where snakebite is a huge issue, like India and Nigeria, as Bangor University molecular zoologist Anita Malhotra tells the Atlantic.

Antivenoms made from lab-grown venom glands are likely years away, but the organoids could also be a big step for studying toxin production in more detail than previously possible. With the cells isolated from the rest of the snake, researchers might be able to look at how they can produce toxic chemicals without damaging themselves, for example.

Clevers tells Discover, We do the most interesting work when we dont have a proposal and just try things.

Continued here:
The Future of Antivenom May Involve Mini Lab-Grown Snake Glands - Smithsonian.com

Fighting cancer with every step to Patagonia – Essex News Daily

Photo Courtesy of Michael MankowichAbove, Michael Mankowich and his wife, Kathleen, in Patagonia

NUTLEY, NJ When Nutley resident Michael Mankowichs lower back started to bother him, he figured it was a souvenir from his earlier athletic days. Mike, 58, had been a top-notch wrestler at 132 pounds at Long Islands Commack North High School. Hed been an all-American, in fact, as well as a two-time all-Ivy, three-time New York state champ and three-time EIWA tournament placer as a wrestler at Cornell University. An old wrestlers injury was all it was, he figured, a physical reminder of a quick takedown of an opponent 40 years long forgotten.

But the pain did not go away.

Mike began to see a doctor and a chiropractor, and eventually he got an MRI. The news he received at Memorial Sloan Kettering Cancer Center in February 2017 was not good. He was diagnosed with multiple myeloma, a cancer that attacks the blood plasma cells responsible for creating disease-fighting antibodies.

They figured it out quickly at Sloan, he said recently, seated with his wife, Kathleen, in their Rutgers Place home. I kept it from Kathleen.

With this news, he became withdrawn, and his wife realized something was wrong. Mike told her what he had learned, and, as so often happens when a couple puts their heads together, they found some reason for hope: multiple myeloma is a blood disease in the bone marrow and, as such, does not metastasize.

Thats where all the action takes place, in the bone marrow, Mike said. You have to keep your chin up.

For treatment, he became part of a six-month chemotherapy clinical study. Mike was glad to be in the study, because most multiple myeloma patients go on chemotherapy for three months and then undergo a stem-cell transplant. He, however, would not.

A stem-cell transplant blows out the immune system, he said.

Kathleen, an administrative coordinator at Felician University School of Nursing, said her husband, a real estate management employee, did not break stride and never missed the commute to New York City during the clinical study.

A member of Nutley High Schools Class of 1976, Kathleen got on the computer.

When your spouse is diagnosed with an incurable cancer, you do a bit of research, she said.

She discovered the Multiple Myeloma Research Foundation website and learned it was founded 30 years earlier by a woman named Kathy Giusti, who was living with the disease.

That gave me hope, Kathleen said.

She also learned about a collaboration between MMRF and CURE Media Group called Moving Mountains for Multiple Myeloma, or MM4MM.

This collaboration promotes endurance events, undertaken by multiple myeloma patients, to places like Mount Fuji, Mount Kilimanjaro and Iceland. The treks raise money for research, as well as public awareness about the disease. A patient selected to participate in one of these exotic treks had to raise funds, but the trip itself was underwritten by Celgene, a pharmaceutical company headquartered in Summit.

Mike was interested and applied in November 2018 for a spot on a team going to Patagonia. He was interviewed and accepted on condition of raising $10,000 for MMRF research. He suggested that Kathleen accompany him, and they eventually raised $30,000 through social media and by asking friends, family and neighbors.

The online MMRF page devoted to Mikes fundraising shows a photograph of him with his arms around Kathleen and their daughter, Mary, a Class of 2020 NHS student.

In a letter featured on the page, Mike informs the reader that MMRF is one of the worlds leading private funders of myeloma research, with 10 new treatments approved by the Food and Drug Administration.

In August 2019, Mike and Kathleen were flown to Oregon to meet their teammates and to get a taste of what was in store for them in Patagonia. According to the MM4MM website: Each team is carefully selected, representing a microcosm of the myeloma community patients, caregivers, health care professionals and clinical trials managers, as well as representatives from our pharma partners, from CURE Magazine and the MMRF to emphasize the collaboration necessary to drive toward cures.

The foundation sent the group to Mount Hood, Mike said. It was the first time we met. What a great group of people. There were around 15 from all over the country, and there was one other couple, but no one else from New Jersey.

Four other multiple myeloma patients were in the group, he said. he team climbed for nine hours and then headed home.

To prepare for the trip to Patagonia, a region containing part of the Andes mountain range, Mike and Kathleen began a regime of long walks. For instance, theyd walk from Nutley to South Orange and went hiking in New Yorks Harriman State Park.

The MMRF website described the journey as one of arduous adventure: This team will traverse Patagonia crossing over glaciers, through deep valleys, and ascending challenging peaks. This is a powerful and life-changing experience, as the team overcomes challenges, pushes beyond perceived limits and honors loved ones and friends living with multiple myeloma.

For the trek, the team flew to El Calafate, Argentina. As the team embarked on different climbs, documentary filmmakers accompanied them.

The hiking was physically difficult, Mike said. We hiked in rain and incredible winds. In one particular hike, as soon as you felt the winds, you hit the ground. I was surprised nobody got hurt. Some of those slopes were pretty steep. But the scenery was unworldly, and there were condors.

Both Mike and Kathleen agreed that the most memorable sight was La Condorera, which their itinerary described as a nearly vertical massif, offering a home to one of the greatest concentrations of endangered condors in the world. A massif is a group of mountains standing apart from other mountains.

It was a difficult hike, Kathleen said. Youre ready to pass out getting to the top. But its so worth it. The panorama is a view of glaciers and condors. It was spectacular.

Mike and Kathleen returned home on Nov. 16, but there were no goodbyes at the airport. The team had grown so incredibly close that everyone felt they would be seeing each other again, a feeling grounded in the knowledge that multiple myeloma can be challenged and hopefully, one day, defeated.

Our goal in all of this is that you can have multiple myeloma and still do incredible things, Kathleen said.

Its an incentive to other patients to get out there and enjoy their lives, Mike said. And find a cure for multiple myeloma. I have a little bias. I have it.

FEATURED, MOBILE

Go here to read the rest:
Fighting cancer with every step to Patagonia - Essex News Daily

New Gene Therapy Successfully Sends Six Patients With Rare Blood Disorder Into Remission – IFLScience

Six patients with a rare blood disease are now in remission thanks to a new gene therapy. The condition, known as X-CGD, weakens the immune system leaving the body vulnerable to a range of nasty infections and shortens a persons lifespan. It is normally treated using bone marrow transplants, but matching donors to patients can be tricky and time-consuming and the procedure comes with risks.

A team led by UCLA recently treated nine people with the disease and six successfully went into remission, allowing them to stop other treatments. All six patients are doing well and havent suffered any adverse effects.

X-CGD is a form of chronic granulomatous disease (CGD). People with CGD have an inherited mutation in one of five genes involved in helping their immune system attack invading microbes with a burst of chemicals. This means that CGD sufferers have weaker immune systems than healthy people, so they have a greater risk of getting infections. These infections can be life-threatening, particularly if they affect the bones or cause abscesses in vital organs.

X-CGD is the most common type of CGD and only affects males. It is caused by a mutation in a gene on the X-chromosome. Current treatments are limited to targeting the actual infections with antibiotics as well as bone marrow transplants. Bone marrow contains stem cells that develop into white blood cells, so bone barrow from a healthy donor can provide a CGD patient with healthy white blood cells that can help their body to fend off disease.

However, bone marrow transplants are far from ideal. The patient has to be matched to a specific donor, and the body can reject the implanted bone marrow. That means that following a transplant, the patient needs to take anti-rejection drugs for at least six months.

For their new treatment, researchers removed blood cell-forming stem cells from the patients themselves and genetically modified them so that they no longer carried the unwanted mutation. Then, the edited stem cells were returned to their bodies, ready to produce healthy new infection-fighting white blood cells.

This is the first time this treatment has been used to try to correct X-CGD. The researchers followed up with the nine patients but sadly, two passed away within three months of the treatment. Its important to note that their deaths were not a result of the treatment but of rather severe infections that they had been suffering from for a long time. The remaining seven were followed for 12 to 36 months all remain free from infections related to their condition, and six have been able to stop taking preventative antibiotics entirely. The results are reported in Nature Medicine.

None of the patients had complications that you might normally see from donor cells and the results were as good as youd get from a donor transplant or better, said Dr Donald Kohn, a member of theEli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLAand a senior author of the paper.

Whats more, four new patients have also been treated since the initial research was conducted. None experienced any adverse reactions and all remain infection-free. Now, the team plans to conduct a bigger clinical trial to further test the safety and efficacy of their new treatment, with the hopes that it may one day become available to the masses.

Read more:
New Gene Therapy Successfully Sends Six Patients With Rare Blood Disorder Into Remission - IFLScience

The Asia Pacific human microbiome market is expected to reach US$ 207.81 Mn in 2025 from US$ 41.73 in 2017 – Yahoo Finance

The market is estimated to grow with a CAGR of 22. 8% from 2018-2025. The growth of the market is driven by the factors such as rising chronic disease due to change in lifestyle and growing interest in human microbiome treatment approach.

New York, Jan. 30, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Asia Pacific Human Microbiome Market to 2025 - Regional Analysis and Forecasts by Product, Disease, Application, and Country" - https://www.reportlinker.com/p05764187/?utm_source=GNW Whereas, stringent regulatory environment and lack of awareness about human microbiome science is likely to have a negative impact on the growth of the market in the coming years.

Probiotics, prebiotics dietary supplements and foods that contain live microbes have been studied thoroughly to assess their effects on human health.The Gut Health Congress was held in Hong Kong Asia in 2018, the conference explore in detail of diet & personalised nutrition, gastrointestinal microbiome and several case studies with regards to clinical studies, diagnostics studies, treatment methods, biomarker developments, molecular therapy and gastrointestinal diseases.

Also, the 5th Microbiome R&D and Business Collaboration Congress was held in Taiwan, Asia in March 2019, the conference focused on recent developments in gut microbiome, skin microbiome, infant, women and oral health, therapeutics, microbiome and diet.Also, many companies are designing and developing many microbiome therapies. Thus, the increasing focus on human microbiome therapies is the prime factor driving the growth of human microbiome market in the coming years.

Japan is anticipated to lead the adoptions of Human microbiome across the Asia Pacific region through the forecast period.Researchers from Japan are using the outcomes of studies on centenarians in the country to try and produce new products that will replicate the beneficial aspects of their microbiota.

The goal of the collaboration is to solve few of the major technological hurdles in advancing stem cell research. Moreover, Cykinso (Tokyo) received the US$ 2.3 million (270 million yen) funds from the Regional Health Care Industry Support Fund, develop and sell Mykinso or a test kit for intestinal flora. The company plans to use the funds for business development purposes, which include using the data collected from the intestinal flora tests to develop a system for offering nutritional guidance. Thus, the investments and the initiatives taken by the government are likely to propel the growth of the market in the forecast period.

Exhibit: Rest Of Asia Pacific Human microbiome Market Revenue and Forecasts to 2027 (US$ Bn)

ASIA PACIFIC HUMAN MICROBIOME- MARKET SEGMENTATIONBy ProductProbioticsFoodsPrebioticsMedical FoodsDiagnostic DeviceDrugsSupplementsASIA PACIFIC HUMAN MICROBIOME- MARKET SEGMENTATIONBy DiseaseObesityDiabetesAutoimmune DisordersCancerMental DisordersOthersASIA PACIFIC HUMAN MICROBIOME- MARKET SEGMENTATIONBy ApplicationTherapeuticsDiagnostics

By CountryU.S.CanadaMexico

Companies MentionedEnteromeMicroBiome Therapeutics, LLCRebiotix Inc.Yakult Honsha Co., Ltd.Osel Inc.Vedanta Biosciences, Inc.Metabiomics CorporateSynthetic Biologics, Inc.DuPontBiomX Ltd.

Reasons to BuySave and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the human microbiome market.Highlights key business priorities in order to assist companies to realign their business strategies.The key findings and recommendations highlight crucial progressive industry trends in the global human microbiome market, thereby allowing players across the value chain to develop effective long-term strategies.Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.Read the full report: https://www.reportlinker.com/p05764187/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Story continues

Clare: clare@reportlinker.comUS: (339)-368-6001Intl: +1 339-368-6001

See the original post here:
The Asia Pacific human microbiome market is expected to reach US$ 207.81 Mn in 2025 from US$ 41.73 in 2017 - Yahoo Finance

The 5 Best Traits Of Micropreneurs, The Smallest Of Small Business Owners – Forbes

Even though I've taken a full-time role writing content for a fintech company, I'm still running my content agency part-time. I will always be an entrepreneur at heartnay, a micropreneur, which I've written about many times.

A micropreneur (or microbusiness) is one that operates on a very small scale, with no more than five employees. We micropreneurs are a breed all our own, and there's plenty to admire about us. So let's pat ourselves on the back, shall we?

Whether youre a micropreneur yourself or thinking about hiring or partnering with one, here are the ... [+] key traits that make us so successful as entrepreneurs.

Whether youare a micropreneur yourself or are thinking about hiring or partnering with one, here are some of our best traits:

When there's no one around to help you solve a problem, what do you do? Solve it, of course. Micropreneurs rely on themselves togit-'er-done, and that makes us strong. It's funnynow that I'm working with an extraordinary team of people in my new job, I realize how long I've been problem-solving on my own. I've gotta say, it's kind of amazing to find people whom I can also trust to help find a solution as good as (or better than) what I would have come up with on my own. And the fact that I've been doing that solo for so many years makes me a great asset to the team.

The drawback to this trait:I guess in my personal life, this isn't always an asset. Sometimes my friends just want to vent about a problem they're having, and I'm already on top of trying to solve it!

Once a micropreneur, always a micropreneur. I don't know one person who has owned a business, shut it down, and never started something new. I myself can count at least five businesses I've started (going back to college when I launched Snazzy Baskets, a custom gift basket brand that didn't make it long). I know in my heart I will start more businesses in the future; it's exciting to wonder what they'll be centered on.

It's like our brains are wired to find opportunities. Saying we're opportunistic isn't accurate; it's more that we find gaps in existing solutions or come up with new and better ways to do things. And that is what makes for the innovation that the world turns on.

The drawback to this trait:We are never, ever satisfied. There's always a better way, and looking for it can be exhausting (see #1).

Other Articles FromAllBusiness.com:

Ask 100 micropreneurs how they manage their daily tasks, and you'll get 100 answers. Maybe 102. That's because we don't prescribe to how others do things; we need to forge our own paths. For me, my day consists of constantly being pinged by Google Calendar tasks, as well as Alexa shouting reminders to me from the kitchen. Sometimes, just for fun, I'll write things on paper.

I love that we micropreneur types are unique and that we don't take the path most traveled for anything we do. I love hearing how other business owners manage things and sometimes modify their solutions.

The drawback to this trait: Ever heard the phrase "Don't reinvent the wheel"? Well ... we can't help doing exactly that, over and over.

Being a micropreneur doesn't mean we are always isolated (though, yes, it sometimes does). We don't need guidance, which makes us uber-productive in our home offices away from other humans. But when we are part of a team, we also thrive. We're like the kid in your school group project who essentially carried the slackers. Because we have such high expectations for our own work, we apply the same diligence when we're working with others.

The drawback to this trait: It's probably hard to have such a go-getter on a team for those who don't operate the same way. It can be easy for us to dominate a project. It's the Type A in us coming out.

So, on a personal note, I'm single. I have engaged in more dating app conversations than I care to count, and despite advice telling me not to ask this (apparently, it's a very clich thing to do), I actually like asking what people do for a living. Because I'm genuinely curious.

Ooh, you're an engineer in the aerospace industry? What sort of technologies are we launching into space?

A doctor involved in stem cell research? Tell me more!

I like understanding what people do and what attracted them to that role. I'm the same with my marketing clients: I want to know what makes their businesses tick so I can make it shine through words.

The drawback to this trait: Again, I think a saying communicates it all: "Curiosity killed the cat." When we spend so much time being curious or going down a research rabbit hole (I know about those), we are less productive.

Micropreneurs are entrepreneurs, certainly, but they're also creatures of their own design. If you are a micropreneur, what other qualities do you love about yourself?

RELATED:Take the 4-Week Micropreneur Challenge to Bring Your Small Business to the Next Level

This article was originally published on AllBusiness. See all articles by Susan Guillory.

More here:
The 5 Best Traits Of Micropreneurs, The Smallest Of Small Business Owners - Forbes

Stem Cell Banking Outsourcing Market Competitive Research And Precise Outlook 2019 To 2025 – NY Telecast 99

The Stem Cell Banking Outsourcing Market Perspective, Comprehensive Analysis along with Major Segments and Forecast, 2019-2025. The Stem Cell Banking Outsourcing market report is a valuable source of data for business strategists. It provides the industry overview with market growth analysis with a historical & futuristic perspective for the following parameters; cost, revenue, demands, and supply data (as applicable). The report explores the current outlook in global and key regions from the perspective of players, countries, product types and end industries. This Stem Cell Banking Outsourcing Market study provides comprehensive data that enhances the understanding, scope, and application of this report.

Top Companies in the Global Stem Cell Banking Outsourcing MarketCCBC, CBR, ViaCord, Esperite, Vcanbio, Boyalife, LifeCell, Crioestaminal, RMS Regrow, Cordlife Group, PBKM FamiCord, cells4life, Beikebiotech, StemCyte, Cryo-cell, Cellsafe Biotech Group, PacifiCord, Americord, Krio, Familycord, Cryo Stemcell.

Stem Cell Banking refers to the human stem cell transplantation for the purpose, with acquisition, processing, preservation and provides the ability to differentiate stem cell storage bank, has been called the life bank.

https://www.marketinsightsreports.com/reports/01231062511/global-stem-cell-banking-outsourcing-market-size-status-and-forecast-2019-2025/inquiry?Mode=46&Source=NY

The Stem Cell Banking Outsourcing market can be divided based on product types and its sub-type, major applications and Third Party usage area, and important regions.

This report segments the global Stem Cell Banking Outsourcing Market on the basis ofTypesare:Umbilical Cord Blood Stem Cell, Embryonic Stem Cell, Adult Stem Cell, Other

On The basis Of Application, the Global Stem Cell Banking Outsourcing Market is Segmented into:Diseases Therapy, Healthcare

https://www.marketinsightsreports.com/reports/01231062511/global-stem-cell-banking-outsourcing-market-size-status-and-forecast-2019-2025/discount?Mode=46&Source=NY

Regions are covered by Stem Cell Banking Outsourcing Market Report 2019 To 2025.

North America, Europe, China, Japan, Southeast Asia, India.North America (USA, Canada and Mexico).Europe (Germany, France, UK, Russia and Italy).Asia-Pacific (China, Japan, Korea, India and Southeast Asia).

Significant Features that are under Offering and Key Highlights of the Reports:

-Detailed overview of Stem Cell Banking Outsourcing Market-Changing Stem Cell Banking Outsourcing market dynamics of the industry-In-depth market segmentation by Type, Application etc.-Historical, current and projected Stem Cell Banking Outsourcing market size in terms of volume and valueRecent industry trends and developments-Competitive landscape of Stem Cell Banking Outsourcing Market-Strategies of key players and product offerings-Potential and niche segments/regions exhibiting promising growth.

https://www.marketinsightsreports.com/reports/01231062511/global-stem-cell-banking-outsourcing-market-size-status-and-forecast-2019-2025?Mode=46&Source=NY

We Also Offer Customization on report based on specific client Requirement:

Free country Level analysis for any 5 countries of your choice.Free Competitive analysis of any 5 key market players.Free 40 analyst hours to cover any other data point.

In this study, the years considered to estimate the market size of Stem Cell Banking Outsourcing are as follows:

History Year: 2014-2018Base Year: 2018Estimated Year: 2019Forecast Year 2019 to 2025

Market Insights Reports is an online market research reports library of 500,000 in-depth studies of over 5000 micro markets. Market Insights Reports offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more.

Irfan Tamboli Market Insights ReportsPhone: + 1704 266 3234 | +91-750-707-8687sales@marketinsightsreports.com | irfan@marketinsightsreports.com

Follow this link:
Stem Cell Banking Outsourcing Market Competitive Research And Precise Outlook 2019 To 2025 - NY Telecast 99

Global Stem Cell Reconstructive Market 2019 Revenue, Opportunity, Forecast and Value Chain 2024 – Science of Change

TheGlobalStem Cell ReconstructiveMarket Growth 2019-2024begins with a market overview and covers market research data that is relevant for new market entrants or established players. The report comprehensively prepared with main focus on the segmentation, competitive landscape, geographical growth, market forecast (2019 to 2024) and major market dynamics including drivers, restraints, and opportunities. The report throws light on key production, revenue, and consumption trends. Key strategies of the companies operating in the market along with a detailed analysis of the competition and leading companies of the globalStem Cell Reconstructivemarket has been highlighted in this report. Additionally, a business overview, revenue share, and SWOT analysis of the leading players in the market have been provided in the report.

For each manufacturer covered, this report analyzes its manufacturing sites, capacity, production, ex-factory price, revenue, and market share in the global market. The followingManufacturersare covered:Osiris Therapeutics, NuVasive, Cytori Therapeutics, Takeda (TiGenix), Cynata, Celyad, Medi-post, Anterogen, Molmed

DOWNLOAD FREE SAMPLE REPORT:https://www.fiormarkets.com/report/global-stem-cell-reconstructive-market-growth-status-and-382312.html#sample

Market Bifurcation:

The report splits the globalStem Cell Reconstructivemarket on the basis of product and segmentation. The study includes significant sectors and categories of the market. Both rapidly and slowly rising segments of the market are analyzed. The market share and the size of each division and sub-division are covered in this report. The current and upcoming opportunities in the market are included in this research study.

From a global perspective, this report represents the overall market size by analyzing historical data and future prospects. Regionally, this report categorizes the production, apparent consumption, export and import in

Some Notable Report Offerings

ACCESS FULL REPORT:https://www.fiormarkets.com/report/global-stem-cell-reconstructive-market-growth-status-and-382312.html

Moreover, the globalStem Cell Reconstructivemarket analyzes the development patterns of the business through authentic investigation and evaluations of future prospects dependent on complete research. The market measure regarding volume with last years growth amount and revenue is planned for the review time span (2019-2024). This report quickly delivers the market patterns, size, development, and estimation for the period 2019-2024. This analysis report also assists rivals as per particular areas for development and compound growth rate.

Contact Us

Mark StoneSales ManagerPhone:+1-201-465-4211Email:[emailprotected]Web:www.fiormarkets.com

See more here:
Global Stem Cell Reconstructive Market 2019 Revenue, Opportunity, Forecast and Value Chain 2024 - Science of Change